Interestingly, certain cancers with either K- or H-Ras mutations can still be sensitive to TRAILs as other receptors and downstream signaling components may affect DR internalization via macropinocytosis (Drosopoulos et al., 2005; Wang et al., 2015). This evidence concerns the gene HRAS and cancer.